Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Daniel

Showing results (1491-1500 of 1,562) with videos related to

Pageof 157
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2024
Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19Carolyn T Bramante, Kenneth B Beckman, Tanvi Mehta, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical TrialCarolyn T Bramante, Kenneth B Beckman, Tanvi Mehta, et al.
Nature Chemical Biology|May 11, 2021
Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivoChristian Dubiella, Benika J Pinch, Kazuhiro Koikawa, et al.
Nature|July 19, 2023
A common allele of HLA is associated with asymptomatic SARS-CoV-2 infectionDanillo G Augusto, Lawton D Murdolo, Demetra S M Chatzileontiadou, et al.
Nature|April 15, 2021
AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrityEmiliano Maiani, Giacomo Milletti, Francesca Nazio, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathwayMotoyuki Tsuda, Dove Keith, Colin J Daniel, et al.
Cell Reports. Medicine|July 15, 2022
Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19Dorien Feyaerts, Julien Hédou, Joshua Gillard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2025
Long-COVID incidence proportion in adults and children between 2020 and 2024Hannah Mandel, Yun J Yoo, Andrea J Allen, et al.
Medrxiv : the Preprint Server for Health Sciences|March 10, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Science Advances|July 31, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Pageof 157

Showing results (1491-1500 of 1,562) with videos related to

Sort By:
Pageof 157
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2024
Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19Carolyn T Bramante, Kenneth B Beckman, Tanvi Mehta, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical TrialCarolyn T Bramante, Kenneth B Beckman, Tanvi Mehta, et al.
Nature Chemical Biology|May 11, 2021
Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivoChristian Dubiella, Benika J Pinch, Kazuhiro Koikawa, et al.
Nature|July 19, 2023
A common allele of HLA is associated with asymptomatic SARS-CoV-2 infectionDanillo G Augusto, Lawton D Murdolo, Demetra S M Chatzileontiadou, et al.
Nature|April 15, 2021
AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrityEmiliano Maiani, Giacomo Milletti, Francesca Nazio, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathwayMotoyuki Tsuda, Dove Keith, Colin J Daniel, et al.
Cell Reports. Medicine|July 15, 2022
Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19Dorien Feyaerts, Julien Hédou, Joshua Gillard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2025
Long-COVID incidence proportion in adults and children between 2020 and 2024Hannah Mandel, Yun J Yoo, Andrea J Allen, et al.
Medrxiv : the Preprint Server for Health Sciences|March 10, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Science Advances|July 31, 2021
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J Peluso, Saki Takahashi, Jill Hakim, et al.
Pageof 157